Gilead defends Truvada pricing during House hearing

Chairman and CEO Daniel O'Day defended Gilead's pricing of HIV PrEP drug Truvada at a congressional hearing Thursday.

Democrats led by House Oversight and Reform Committee Chair Elijah Cummings (D-Md.) pressed O'Day on the

Read the full 330 word article

User Sign In